Lipid Nanoparticle Stabilization via Cryoprotectants
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
The delivery of nucleic acids to cells is hindered by their instability and low cell permeability, and existing lipid-containing nanoparticles lack improvements in safety, efficacy, and specificity.
Innovation Solution
A stabilized lipid nanoparticle (LNP) formulation is developed, comprising ionizable and structural lipids, along with a stabilizing agent such as a cryoprotectant, chelator, or antioxidant, which mitigates degradation and improves storage stability, reducing phase separation and immunogenicity.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If lipid-containing nanoparticles are used for nucleic acid delivery, then cell permeability is improved, but stability and storage reliability deteriorate due to phase separation and degradation
Solution Approach 1:
The patent applies preliminary action by incorporating stabilizing agents (cryoprotectants, chelators, antioxidants) into the LNP formulation before storage. This preventive measure protects the nanoparticles from degradation and phase separation during storage, addressing the stability issue before it occurs. The stabilizing agents are pre-added to mitigate oxidative stress and maintain structural integrity throughout the storage period.
Solution Approach 2:
The patent employs parameter changes by optimizing the composition ratios of lipids, cholesterol, and stabilizing agents in the formulation. By adjusting these chemical parameters and the physical state (frozen vs. aqueous), the patent achieves improved storage stability while preventing phase separation. The specific molar ratios and concentrations are tuned to enhance reliability without compromising composition stability.
2Reliability
If stabilizing agents are added to prevent degradation, then storage stability is improved, but formulation complexity increases
Solution Approach 1:
The patent applies universality by selecting stabilizing agents that perform multiple functions simultaneously. For example, certain antioxidants not only prevent oxidative degradation but also maintain lipid fluidity and prevent aggregation. The chelators serve both to bind metal ions and stabilize the overall formulation. This multi-functionality reduces the number of separate additives needed, thereby limiting the increase in formulation complexity while achieving improved storage stability.
Solution Approach 2:
The patent uses stabilizing agents as intermediaries between the LNP formulation and the storage environment. These agents mediate the interaction between the nanoparticles and external stressors (oxidation, freeze-thaw cycles), protecting the LNPs without requiring complex structural modifications. The stabilizing agents act as a buffer layer, simplifying the overall system by handling stress management externally.
3Stability of the object's composition
If frozen formulation is used for storage, then stability is improved, but manufacturing and handling difficulty increases
Solution Approach 1:
The patent applies parameter changes by optimizing the freezing protocol parameters (cooling rate, final storage temperature, container type) to achieve stable frozen formulations. By carefully controlling these parameters, the patent prevents ice crystal formation that could damage LNPs while maintaining storage stability. The formulation is designed to be freeze-thaw resistant, allowing for easier manufacturing and handling compared to formulations requiring strict avoidance of freezing.
Solution Approach 2:
The patent applies preliminary action by incorporating cryoprotectants into the formulation before freezing. This preparatory step protects the LNPs from freeze-induced damage, enabling the use of frozen storage without compromising manufacturing ease. The cryoprotectants are added in advance to prevent ice crystal formation and maintain nanoparticle integrity throughout the freezing and thawing processes.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The formulation maintains enhanced stability and encapsulation efficiency, with reduced immunogenicity and increased therapeutic index, allowing for effective delivery of nucleic acids while minimizing degradation and immune response.
Implementation Method 1
the stabilizing agent comprises a cryoprotectant, a chelator, an antioxidant, or any combination thereof
Implementation Method 2
the stabilizing agent comprises a cryoprotectant, a chelator, an antioxidant, or any combination thereof
Implementation Method 3
the stabilizing agent comprises a cryoprotectant, a chelator, an antioxidant, or any combination thereof
Implementation Method 4
the stabilizing agent that mitigates the degradation of the LNPs... wherein the LNPs comprise an ionizable lipid and a structural lipid
Data Source
AI summary
The disclosure features a lipid nanoparticle (LNP) formulation comprising a plurality of LNPs and a stabilizing agent that mitigates the degradation of the LNPs or a subpopulation thereof. Lipid nanoparticles further including therapeutics and/or prophylactics such as RNA are useful in the delivery of therapeutics and/or prophylactics to mammalian cells or organs to, for example, regulate polypeptide, protein, or gene expression. Methods of manufacturing LNP formulations and screening for a stabilizing agent are also disclosed.